XLKD1 Antibody (N-term) Blocking Peptide
€363.00
In stock
SKU
AC-BP2015a
Background:
One of the key groups of molecules regulating leukocyte and tumour cell migration is the glycosaminoglycan hyaluronan (HA). In inflammation, the exit of leukocytes across vascular endothelium to the underlying tissues involves interactions with cell surface lectin-like receptors on the leukocytes that bind HA on the lumenal surface of the endothelium. During normal tissue homeostasis and after tissue injury, HA is mobilized from these sites through lymphatic vessels to the lymph nodes where it is degraded before entering the circulation for rapid uptake by the liver. Lymphatic vessel endothelial hyaluronan receptor (LYVE)-1 is a major receptor for HA on the lymph vessel wall. LYVE-1 is expressed primarily on lymphatic vessel endothelium and is likely to be involved in regulating the traffic of leucocytes and tumour cells to lymph nodes.
Other Names:
Lymphatic vessel endothelial hyaluronic acid receptor 1, LYVE-1, Cell surface retention sequence-binding protein 1, CRSBP-1, Extracellular link domain-containing protein 1, Hyaluronic acid receptor, LYVE1, CRSBP1, HAR, XLKD1
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP2015a was selected from the N-term region of human XLKD1 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: LYVE1
Gene ID: 10894
Primary Accession: Q9Y5Y7
Other Accession: NP_006682
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
One of the key groups of molecules regulating leukocyte and tumour cell migration is the glycosaminoglycan hyaluronan (HA). In inflammation, the exit of leukocytes across vascular endothelium to the underlying tissues involves interactions with cell surface lectin-like receptors on the leukocytes that bind HA on the lumenal surface of the endothelium. During normal tissue homeostasis and after tissue injury, HA is mobilized from these sites through lymphatic vessels to the lymph nodes where it is degraded before entering the circulation for rapid uptake by the liver. Lymphatic vessel endothelial hyaluronan receptor (LYVE)-1 is a major receptor for HA on the lymph vessel wall. LYVE-1 is expressed primarily on lymphatic vessel endothelium and is likely to be involved in regulating the traffic of leucocytes and tumour cells to lymph nodes.
Other Names:
Lymphatic vessel endothelial hyaluronic acid receptor 1, LYVE-1, Cell surface retention sequence-binding protein 1, CRSBP-1, Extracellular link domain-containing protein 1, Hyaluronic acid receptor, LYVE1, CRSBP1, HAR, XLKD1
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP2015a was selected from the N-term region of human XLKD1 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: LYVE1
Gene ID: 10894
Primary Accession: Q9Y5Y7
Other Accession: NP_006682
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
| Is Featured? | No |
|---|
Write Your Own Review